Keeping von Willebrand Factor under Control: Alternatives for ADAMTS13

被引:14
|
作者
Tersteeg, Claudia [1 ]
Fijnheer, Rob [2 ]
Pasterkamp, Gerard [2 ]
de Groot, Philip G. [2 ]
Vanhoorelbeke, Karen [1 ]
de Maat, Steven [2 ]
Maas, Coen [2 ]
机构
[1] Katholieke Univ Leuven, IRF Life Sci, Lab Thrombosis Res, Campus Kulak Kortrijk, Kortrijk, Belgium
[2] UMC Utrecht, Lab Clin Chem & Hematol, Heidelberglaan 100,G-03-550, NL-3584 CX Utrecht, Netherlands
来源
SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2016年 / 42卷 / 01期
关键词
ADAMTS13; plasmin; VWF; thrombotic thrombocytopenic purpura; thrombotic microangiopathy; THROMBOTIC THROMBOCYTOPENIC PURPURA; NEUTROPHIL EXTRACELLULAR TRAPS; UROKINASE RECEPTOR EXPRESSION; TISSUE-PLASMINOGEN-ACTIVATOR; FACTOR-CLEAVING PROTEASE; DNA TRAPS; VONWILLEBRAND-FACTOR; EMERGENCY BYPASS; DISEASE-ACTIVITY; FACTOR MULTIMERS;
D O I
10.1055/s-0035-1564838
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Von Willebrand factor (VWF) is one of the most important proteins of the hemostatic system. Its multimeric state is essential for its natural function to guide platelets to sites of injury. ADAMTS13 is the key protease that regulates the multimeric state of VWF. Without ADAMTS13, VWF multimers can grow to pathologically large sizes. This is a risk factor for the life-threatening condition thrombotic thrombocytopenic purpura (TTP). In this condition, VWF-rich thrombi occlude the microvasculature of various tissues. Intriguingly, a complete ADAMTS13 deficiency does not cause continuous TTP, either in patients or genetically targeted mice. Instead, TTP occurs in episodes of disease, separated by extended periods of remission. This indicates that regulating factors beyond ADAMTS13 are likely involved in this pathologic cascade of events. This raises the question of what really happens when ADAMTS13 is (temporarily) unavailable. In this review, we explore the possible role of complementary mechanisms that are capable of modifying the thrombogenic potential of VWF.
引用
收藏
页码:9 / 17
页数:9
相关论文
共 50 条
  • [21] Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura
    Budde, U.
    Schneppenheim, R.
    HAMOSTASEOLOGIE, 2014, 34 (03): : 215 - 225
  • [22] Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology
    Stepanian, A.
    Cohen-Moatti, M.
    Sanglier, T.
    Legendre, P.
    Ameziane, N.
    Tsatsaris, V
    Mandelbrot, L.
    De Prost, D.
    Veyradier, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 455 - 455
  • [23] Proteolytic Processing of Von Willebrand Factor by Adamts13 and Leukocyte Proteases
    Lancellotti, Stefano
    Basso, Maria
    De Cristofaro, Raimondo
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2013, 5 (01):
  • [24] Mutations in Von willebrand factor render it resistant to cleavage by ADAMTS13
    Desch, Karl
    Ginsburg, David
    PEDIATRIC BLOOD & CANCER, 2007, 48 (06) : 642 - 642
  • [25] von Willebrand Factor, Shear Stress, and ADAMTS13 in Hemostasis and Thrombosis
    Tsai, Han-Mou
    ASAIO JOURNAL, 2012, 58 (02) : 163 - 169
  • [26] Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13
    Cao, Wenjing
    Krishnaswamy, Sriram
    Camire, Rodney M.
    Lenting, Peter J.
    Zheng, X. Long
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (21) : 7416 - 7421
  • [27] Plasma von Willebrand factor and ADAMTS13 concentrations in atrial fibrillation
    Uemura, Takashi
    Kaikita, Koichi
    Yamabe, Hiroshige
    Matsukawa, Masakazu
    Soejima, Kenji
    Tanaka, Yasuaki
    Morihisa, Kenji
    Ogawa, Hisao
    CIRCULATION, 2007, 116 (16) : 585 - 585
  • [28] The Intriguing Relationships of von Willebrand Factor, ADAMTS13 and Cardiac Disease
    Reardon, Benjamin
    Pasalic, Leonardo
    Favaloro, Emmanuel J.
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2021, 8 (09)
  • [29] Increased Von Willebrand factor, decreased ADAMTS13 and thrombocytopenia in melioidosis
    Birnie, Emma
    Koh, Gavin C. K. W.
    Lowenberg, Ester C.
    Meijers, Joost C. M.
    Maude, Rapeephan R.
    Day, Nicholas P. J.
    Peacock, Sharon J.
    van der Poll, Tom
    Wiersinga, W. Joost
    PLOS NEGLECTED TROPICAL DISEASES, 2017, 11 (03):
  • [30] ADAMTS13 and von Willebrand factor concentrations in patients with diabetes mellitus
    Skeppholm, Mika
    Kallner, Anders
    Kalani, Majid
    Jorneskog, Gun
    Blomback, Margareta
    Wallen, Hakan N.
    BLOOD COAGULATION & FIBRINOLYSIS, 2009, 20 (08) : 619 - 626